Increased coexpression of c‐KIT and FLT3 receptors on myeloblasts: Independent predictor of poor outcome in pediatric acute myeloid leukemia

Significance of mutations in FLT3 and c‐KIT genes in AML has been well established, but role of their coexpression has not been evaluated. The aim of this study was to evaluate clinical significance of FLT3 (CD135) and c‐KIT (CD117) coexpression on myeloblasts in AML.

[1]  E. Estey,et al.  Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 , 2004 .

[2]  T. Naoe,et al.  Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. , 2004, Blood.

[3]  Paul M. Schneider,et al.  High-Throughput Analysis of Genome-Wide Receptor Tyrosine Kinase Expression in Human Cancers Identifies Potential Novel Drug Targets , 2004, Clinical Cancer Research.

[4]  M. Graf,et al.  Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies , 2004, European journal of haematology.

[5]  B. Smith,et al.  Response to ‘comparison of “sequential” versus “standard” chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (aml): results of the uk medical research council aml‐r trial’ , 2003, British journal of haematology.

[6]  W. Hiddemann,et al.  The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. , 2003, Blood.

[7]  A. Burnett,et al.  Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML‐R trial , 2001, British journal of haematology.

[8]  A. Órfão,et al.  The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). , 1998, Blood.

[9]  W. Piacibello,et al.  Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts. , 1996, Leukemia.

[10]  L. Stempora,et al.  CD117/CD34 expression in leukemic blasts. , 1996, American journal of clinical pathology.

[11]  D. Hirschstein,et al.  Effects of flt3 ligand on acute myeloid and lymphocytic leukemic blast cells from children. , 1996, Experimental hematology.

[12]  M. Endo,et al.  Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture. , 1996, Leukemia.

[13]  J. Matthews,et al.  Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. , 1994, Blood.

[14]  M. Reuss-Borst,et al.  AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. , 1994, Leukemia.

[15]  H. Kitayama,et al.  Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. , 1991, Blood.

[16]  C. Juttner,et al.  Expression of a 150-kD cell surface antigen identified by monoclonal antibody YB5.B8 is associated with poor prognosis in acute non-lymphoblastic leukaemia. , 1988, Leukemia research.